Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures

Phillip Gutis didn't expect biotech companies Biogen (BIIB) and Eisai to cure his Alzheimer's disease. But the former New York Times reporter did see his participation in a clinical study of the experimental drug, aducanumab, as a step toward finding an Alzheimer's treatment.